Clinical Trial Update: Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions [Phase 1]

View source ↗

Summary

A Phase 1, non-randomized, open-label trial evaluating intralesional nivolumab for high-risk oral premalignant lesions in head and neck cancer patients. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Head and Neck Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING